Recent advances in the understanding and management of mucormycosis

Benoît Pilmis (1, 2, 3, 4) , Alexandre Alanio (5, 2, 6, 7, 8) , Olivier Lortholary (1, 6, 7, 9) , Fanny Lanternier (1, 6, 7, 9)

1 UPD5 - Université Paris Descartes - Paris 5
2 SU - Sorbonne Université
3 Centre d'infectiologie Necker-Pasteur [CHU Necker]
4 Centre hospitalier Saint-Joseph [Paris]
5 UPD7 - Université Paris Diderot - Paris 7
6 Mycologie moléculaire - Molecular Mycology
7 CNRMA - Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
8 Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
9 CHU Necker - Enfants Malades [AP-HP]

Mucormycoses were difficult-to-manage infections owing to limited diagnostic tools and therapeutic options. We review here advances in pathology understanding, diagnostic tools including computed tomography, and serum polymerase chain reaction and therapeutic options.

Keywords: Isavuconazole; Liposomal amphotericin B; Mucormycosis; Reverse Halo sign; PCR

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Mycology

Benoît Pilmis, Alexandre Alanio, Olivier Lortholary, Fanny Lanternier. Recent advances in the understanding and management of mucormycosis. F1000Research, 2018, 7, pp.1429. ⟨10.12688/f1000research.15081.1⟩. ⟨pasteur-02193174⟩